The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of capecitabine in substitution of 5-FU in the chemoradiotherapy regimen for patients with squamous cell carcinoma of the anal canal.
Suilane Coelho Ribeiro
No relevant relationships to disclose
Camila Venchiarutti
No relevant relationships to disclose
Rachel Riechelmann
No relevant relationships to disclose
Erlon Gil
No relevant relationships to disclose
Caio Nahas
No relevant relationships to disclose
Renata Coudry
No relevant relationships to disclose
Daniela Freitas
No relevant relationships to disclose
Daniel F. Saragiotto
No relevant relationships to disclose
Fernando Arruda
No relevant relationships to disclose
Rodrigo Azambuja
No relevant relationships to disclose
Paulo Hoff
No relevant relationships to disclose